



















Tuberculosis (TB) is a major cause of morbidity and 
mortality in sub-Sah aran Africa, especially in the 
southern region of the continent.1 The escalating 
incidence of TB over the past decade is largely 
attributable to the devastating HIV epidemic.2 HIV is 
an important risk factor for the reactivation of latent 
TB infection, and HIV seropositive persons who 
become co-infected with Mycobacterium tuberculosis 
rapidly progress to active TB.3
TB has a relatively high mortality rate in the first few 
days after diagnosis, despite initiation of treatment 
with antituberculosis drugs.4 Postulated causes 
include late presentation with advanced systemic 
inflammatory response, pulmonary embolus secondary 
Adrenocortical function in hospitalised 
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Objective. To assess whether adrenocortical function was compromised in patients with active tuberculosis 
(TB) during the first 5 days of therapy with either a rifampicin-based or ciprofloxacin-based regimen.
Design. Patients were randomised into two groups of 10 each. Adrenocortical function was compared in 
both groups by the measurement of biochemical indices, electrolytes, osmolality and pituitary-adrenocortical 
hormones. Adrenal reserve was assessed by intravenous 250 µg adrenocorticotropin hormone (ACTH) 
stimulation tests.
Setting. Department of Medicine, Johannesburg Hospital.
Subjects. Twenty hospitalised patients who were diagnosed with TB.
Outcome measures. Respiratory rate, pulse rate and blood  pressure were recorded, and urinary sodium and  
osmolality were measured. Serum ACTH, cortisol, dehydroepiandros-terone-sulphate (DHEA-S) and 
aldosterone were assayed.
results. None of the patients demonstrated biochemical evidence of overt adrenal insufficiency. There were 
no significant differences between the two groups before or during therapy for any biochemical indices, 
electrolytes, hormones or calculated osmolality. Mean basal cortisol concentrations were substantially 
elevated and DHEA-S levels were consistently subnormal, resulting in a high cortisol/DHEA-S ratio. In the 
ciprofloxacin group, cortisol responses to ACTH stimulation on day 1 were not significantly lower than on 
day 5. In the rifampicin group, cortisol concentrations decreased at each time point on day 5 compared with 
day 1 (p = 0.001). However, a significantly higher mean incremental rise from the basal cortisol concentration 
was measured on day 5 at 60 minutes (p = 0.04). In the entire cohort of 20 patients, 40% demonstrated an 
incremental cortisol rise of < 250 nmol/l after ACTH stimulation on day 1.
conclusions. Rifampicin did not additionally impair adrenocortical function during the initial period of 
therapy. The high cortisol/DHEA-S ratio might be of clinical relevance.
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to hypercoagulability, or bacterial superinfection 
of damaged lungs.  Another possible cause is 
hypoadrenalism secondary to tuberculous infection 
of the adrenal glands. Hypoadrenalism in TB is 
particularly relevant because cortisol deficiency 
could account for some of the sudden deaths in these 
patients.5 A large study from South Africa published 
in 1986, before HIV became a serious clinical problem, 
found suboptimal responses to ACTH stimulation in 
55% of patients with pulmonary TB.6
Standard TB therapy includes the antibiotic 
rifampicin, which is a potent hepatic enzyme inducer 
that might contribute to adrenal insufficiency by 
accelerating the catabolism of cortisol.7 The objective 
of this prospective study was to assess whether 
adrenocortical function was compromised in patients 
with active pulmonary TB during the initial period of 
therapy with two different antituberculosis regimens, 




Twenty hospitalised patients diagnosed with sputum-
positive TB were studied prospectively. Before 
admission none had received antituberculosis therapy. 
Patients who were pregnant or who were on treatment 
with corticosteroids or any drugs known to interfere 
with steroid metabolism, were excluded. Informed 
consent was obtained from all patients and the 
study was approved by the Human Research Ethics 
Committee of the University of the Witwatersrand, 
Johannesburg.
Design
Patients were randomised into two groups of 10 (5 
men and 5 women in each group), and treated with a 
quadruple antituberculosis regimen containing either 
rifampicin or ciprofloxacin.  In accordance with local 
guidelines, patients in the rifampicin group were 
given 300 mg daily if they weighed < 50 kg, and 450 
mg if  > 50 kg.  Patients in the ciprofloxacin group 
received 500 mg twice daily, irrespective of weight.  
The remainder of the regimen comprised standard 
therapy (isoniazid, ethambutol and pyrazinamide), 
with doses adjusted individually for weight.
The study was designed to compare adrenocortical 
function in the two groups during the first 5 days 
of therapy with either rifampicin or ciprofloxacin.  
Clinical measures of respiratory rate, pulse rate and 
supine blood pressure were recorded before starting 
therapy.  A urine sample was taken for measurement 
of sodium and osmolality.  From day 1 to day 5, 
between 07h00 and 09h00, fasting blood samples were 
taken for the measurement of adrenocorticotropic 
hormone (ACTH), cortisol, dehydroepiandrosterone-
sulphate (DHEA-S) and aldosterone.  On days 1, 3 
and 5, blood samples were also analysed for glucose, 
sodium, potassium, chloride, total CO2, urea and 
creatinine. 
In addition, on days 1 and 5, intravenous ACTH (250 
µg) stimulation tests were performed.  An indwelling 
intravenous cannula was inserted near the antecubital 
fossa and kept patent with heparinised saline, 
and a 30-minute rest period was allowed.  Fasting 
blood samples were taken for basal measurements 
and thereafter 250 µg Synacthen (Novartis Pharma 
AG, Basle, Switzerland) was administered as an 
intravenous bolus.  Additional blood samples were 
taken at 30 minutes and 60 minutes for measurement 
of cortisol, and a normal response was defined as an 
increment of > 250 nmol/l at 60 minutes, based on 
criteria recently recommended for acutely ill patients.8 
Measurement of biochemical indices, 
electrolytes and osmolality 
Plasma glucose levels were determined using a 
standard glucose oxidase method (normal range 3.0 
- 6.0 mmol/l).  Serum electrolytes (sodium, potassium, 
chloride, total CO2, urea and creatinine) and urinary 
sodium were measured with a COBAS Integra 400 
autoanalyser using reagents supplied by Roche 
Diagnostics GmbH, Mannheim, Germany.  Respective 
normal ranges are as follows: sodium 135 - 147 mmol/l 
(serum), 60 - 200 mmol/l (urine); potassium 3.3 - 5.3 
mmol/l; chloride 99 - 113 mmol/l; total CO2 18 - 29 
mmol/l; urea 2.6 - 7.0 mmol/l; creatinine 60 - 120 µmol/
l (men) and 60 - 100 µmol/l (women).  The inter- and 
intra-assay coefficients of variation (CVs) for these 
assays were between 5% and 10%.
The following formula was used to calculate serum 
osmolality: 2 (sodium + potassium) + urea + glucose 
(normal range 280 - 295 mOsm/kg).  Urine osmolality 
was measured with an automatic micro-osmometer 
(Roebling, Berlin, Germany), normal range 50 - 1 200 
mOsm/kg.
The syndrome of inappropriate antidiuretic hormone 
(SIADH) secretion was defined by the combination of 
hyponatraemia (sodium < 130 mmol/l) with low serum 
osmolality (< 280 mOsm/kg), inappropriately high 
urine osmolality compared with serum osmolality, and 
urinary sodium > 20 mmol/l, in the absence of clinical 
volume depletion.9
Assays of pituitary-adrenocortical 
hormones
Serum ACTH, DHEA-S and aldosterone concentrations 
were measured by immunoassay using direct 
chemiluminometric technology and reagents supplied 
by Diagnostics Products Corporation, Los Angeles, 
Calif., USA.  Respective fasting normal ranges are as 
follows: ACTH < 46 ng/l, DHEA-S 4.0 - 13.3 µmol/l 
(men) and 0.9 - 8.7 µmol/l (women) for age range 20 




















- 40 years, and aldosterone < 440 pmol/l (supine).  
Radioimmunoassay kits supplied by ICN BIO medicals, 
Inc., Costa Mesa, Calif., USA were used to measure 
serum cortisol (normal range 190 - 660 nmol/l).  The 
inter- and intra-assay CVs for these assays varied 
between 5% and 10%.
Statistical analysis
Results were analysed using one-way analysis of 
variance (ANOVA) for repeated measures, followed 
by the two-tailed t-test for parametric data and 
Wilcoxon’s rank sum test or signed rank test 
when distribution of the data was non-parametric. 
The effect of ACTH stimulation was analysed by 
comparison of the incremental rises in cortisol, which 
were calculated by subtracting the basal level from 
the peak level attained at 30 minutes and 60 minutes 
(∆ change). Results are expressed as mean ± standard 




Table I shows clinical measurements for the 20 
patients on admission to hospital.  Before start of 
therapy there were no significant differences between 
the two groups in terms of mean age, weight, 
respiratory rate and pulse rate. Patients randomised 
to the ciprofloxacin group had significantly lower 
systolic blood pressure (BP) (p = 0.03) and diastolic 
BP (p = 0.01). One patient in this group refused to be 
tested for HIV status, and of the 19 patients tested, 
1 patient was found to be HIV seronegative and 18 
were HIV seropositive. There were 9 documented HIV 
seropositive patients in each group. Mean baseline 
CD4 counts were not significantly different: rifampicin 
group 192 ± 83/µl and ciprofloxacin group: 171 ± 67/
µl (normal range 500 - 2 010/µl). All 20 patients had 
improved clinically when they were reassessed on  
day 5.
Biochemical indices, electrolytes and 
osmolality before and during therapy 
There were no significant differences between the 
groups treated with either rifampicin or ciprofloxacin 
for any of the variables measured (Table II).  Within 
the rifampicin group, however, the mean glucose 
level on day 5 was significantly lower than on days 
1 and 3 (p = 0.03).  In both groups, mean serum 
sodium values were below the normal range and 
remained low during the period of study.  Mean levels 
of potassium, chloride and total CO2 were all normal 
and were not affected by either drug. Mean urea and 
creatinine concentrations were slightly higher in the 
rifampicin group throughout the study. Concentrations 
of both indices decreased from days 1 and 3 to day 
5, significantly so for urea and creatinine in the 
rifampicin group (p = 0.001) and for creatinine in the 
ciprofloxacin group (p = 0.001). 
Before starting therapy, 7 of the 20 patients (35%) 
were hyponatraemic (mean sodium 126 mmol/l), and 
all 7 patients had some features of SIADH.  In this 
small subgroup, mean serum osmolality was 272 
mOsm/kg, mean urine osmolality was 454 mOsm/kg 
and mean urinary sodium was 31 mmol/l.
Pituitary-adrenocortical hormones 
before and during therapy 
There were no significant differences between the 
groups treated with either rifampicin or ciprofloxacin 
for any of the hormones measured (Table III). Within 
each group, however, mean ACTH levels fluctuated 
and were all higher during the therapy period 
than on day 1. This increase was significant in the 
rifampicin group (p = 0.001). Mean basal cortisol 
concentrations in both groups were substantially 
above the normal range throughout the study, possibly 
reflecting the stress of acute illness. Compared with 
the ciprofloxacin-treated patients, mean cortisol 
concentrations in the rifampicin group were all 
higher, but not significantly so. On rifampicin therapy, 
mean cortisol concentrations decreased, reaching 
significance on day 5 compared with days 1 and 2 
(p = 0.003). Mean DHEA-S levels were consistently 
subnormal and a significant decline from day 1 
through to day 5 was seen in the rifampicin group (p = 
0.007). In the ciprofloxacin group, DHEA-S levels were 
also low without any significant change during the 
study. Mean aldosterone values in both groups were 
variable and all were within the normal range. Values 
were lowest in both groups on day 5, significantly 
so compared with day 1 in the rifampicin group (p = 
0.001).
cortisol responses to intravenous 
ActH (250 µg) stimulation tests
Mean cortisol concentrations at baseline and after 
ACTH stimulation did not differ significantly at any 
 rifampicin ciprofloxacin
 (N = 10) (N = 10)
Age (years) 28 ± 3 35 ± 3
Weight (kg) 51.5 ± 8.7 51.0 ± 4.1
Respiratory rate/min 21 ± 1 20 ± 1
Pulse rate/min 101 ± 3 99 ± 3
Systolic BP (mmHg) 114 ± 7 96 ± 4*
Diastolic BP (mmHg) 76 ± 4 63 ± 3†
*p = 0.03 significantly lower than rifampicin group. 
†p = 0.01 significantly lower than rifampicin group.
table i.       clinical measurements of two groups 
of patients on admission to hospital 
(mean ± SEM)












time point on day 1 or day 5 between the rifampicin 
and ciprofloxacin groups (Fig. 1).  There were no 
significant differences within the ciprofloxacin group 
on day 1 compared with day 5.  However, within 
the rifampicin group, mean cortisol concentrations 
apparently decreased at each time point on day 5 
compared with day 1 (p = 0.001). When expressed as 
an incremental rise from basal, however, levels were, 
in fact, greater on day 5 than on day 1 (30 minutes: 
360 nmol/l (day 5) v. 158 nmol/l (day 1), and 60 
minutes: 615 nmol/l (day 5) v. 348 nmol/l (day 1); p =  
0.04). This was due to the basal cortisol level having 
declined significantly from 1 258 nmol/l on day 1 to 
918 nmol/l on day 5 (p = 0.005). Applying the normal 
cortisol response, defined as an increment of  > 250 
nmol/l at 60 minutes,8 5 patients in the ciprofloxacin 
group and 3 in the rifampicin group were found to 
have inadequate adrenal reserve on day 1; these 
numbers had dropped to 2 in each group by day 5.
Discussion
The primary objective of this study was to establish 
whether adrenocortical function was compromised 
in patients with active pulmonary TB during the 
initial phase of treatment with a rifampicin-based 
regimen. To this end we measured basal serum levels 
of the pituitary-adrenocortical hormones – ACTH, 
cortisol, DHEA-S and aldosterone – and serum cortisol 
responses to intravenous ACTH stimulation tests.
Mean basal cortisol concentrations were substantially 
elevated, almost certainly reflecting the stress of 
the underlying medical condition, as in other acute 
respiratory illnesses.10 In this context, it has been 
proposed that random serum cortisol levels above 938 
nmol/l make adrenal insufficiency unlikely,8 and this 
was clearly evident on day 1 for both our treatment 
groups. Although mean cortisol levels dropped below 
this threshold on day 5 in both groups, this probably 
reflected their improving clinical state owing to 
effective antituberculosis and supportive therapy, 
rather than deteriorating adrenocortical function itself.
DHEA-S concentrations, on the other hand, were 
consistently subnormal, probably as a result of the 
poor health status of the majority of patients in our 
study.11 The discrepancy between high cortisol and 
low DHEA-S levels in our patients is interesting and 
might have clinical relevance.  Reduced output of 
DHEA metabolites in patients with severe TB could 
be detrimental for several reasons.12,13  Effective 
immunity to TB requires a T helper-1 (Th1) pattern 
of cytokine release and experimental animal studies 
have demonstrated that even a minor T helper-2 (Th2) 
component is associated with impaired immunity 
and a non-protective cytokine profile. Exposure of T-
cells to glucocorticoids such as cortisol drives them 
towards a Th2 response, which may both reactivate 
and exacerbate TB. In contrast, DHEA and its 
derivatives have antiglucocorticoid effects in vivo 
and, in the experimental situation, have been shown 
to protect against shifts towards Th2 effects and to 
be associated with enhanced granuloma formation. In 
short, the high cortisol/DHEA-S ratio that occurred in 
our patients may be crucial to both the susceptibility 
and the pathology of disease in TB, and warrants 
further investigation.
         rifampicin group (N = 10)            ciprofloxacin group (N = 10)
 Day 1 Day 3 Day 5 Day 1 Day 3 Day 5
Glucose (mmol/l) 5.3 ± 0.4 5.4 ± 0.4 4.6 ± 0.3* 5.1 ± 0.5 5.0 ± 0.5 5.1 ± 0.4
Sodium (mmol/l) 129 ± 1 133 ± 1 133 ± 1 133 ± 2 133 ± 1 135 ± 1
Potassium (mmol/l) 3.7 ± 0.1 3.7 ± 01 3.9 ± 0.1 3.9 ± 0.1 3.7 ± 0.1 3.8 ± 0.1
Chloride (mmol/l) 99 ± 2 102 ± 1 102 ± 1 99 ± 2 102 ± 2 105 ± 2
Total CO2 (mmol/l) 20 ± 1 20 ± 1 20 ± 1 22 ± 1 21 ± 1 20 ± 1
Urea (mmol/l) 4.5 ± 1.0 4.2 ± 0.7 3.1 ± 0.4† 3.2 ± 0.6 3.3 ± 0.3 2.7 ± 0.3
Creatinine (µmol/l) 84 ± 6 80 ± 6 73 ± 7‡ 75 ± 6 74 ± 3 68 ± 2*
Calculated osmolality
(mOsm/kg) 277 ± 2 283 ± 2 282 ± 2 283 ± 3 282 ± 2 287 ± 3
*p = 0.03   day 1, 3 v. day 5.
†p = 0.001 day 1, 3 v. day 5.
‡p = 0.001 day 1, 3 v. day 5.
table ii.       Fasting serum biochemical indices, electrolytes and osmolality in two groups of patients 
before and during therapy (mean ± SEM)
Fig. 1. Serum cortisol responses following intravenous ACTH 
(250 µg) stimulation tests in two groups of patients with 
pulmonary TB treated with rifampicin (N = 10) and ciprofloxacin 
(N = 10).  Results are expressed as mean  ± SEM. Rifampicin day 
1 v. day 5 * p = 0.001 for each of the time points.




















In the rifampicin group, cortisol responses to ACTH stimulation tests 
were well above normal, except for 3 patients on day 1 and 2 patients 
on day 5. However, the dose of Synacthen (250 µg) administered was 
supra-physiological, with reduced sensitivity compared with a low 
dose (1 µg),14 and this could have masked more extensive impairment 
of function produced by rifampicin. This might apply particularly 
to HIV-infected patients who are acutely ill.15 Nevertheless, the 
greater incremental post-stimulation cortisol response at each of 
the time points on day 5 in this group of patients is an indication 
of unimpaired cortisol metabolism, although (as previously stated) 
their improved clinical state, owing to the effective antituberculosis 
therapy, may also have had some effect. Overall, in the entire cohort 
of 20 patients,8 demonstrated relatively impaired cortisol responses to 
ACTH stimulation on day 1, using the cut-off level of < 250 nmol/l.8  
However, since the basal cortisol level in all but 3 cases was well above 
938 nmol/l, the clinical relevance of this observation is uncertain. 
Furthermore, considerable ambiguity exists when defining the ideal 
cut-offs for diagnosing relative adrenal insufficiency after ACTH 
stimulation in different stress situations.16
It transpired that no subject demonstrated biochemical evidence of 
overt adrenocortical insufficiency in the entire group of 20 patients.  
In this regard, our finding is in keeping with the low incidence of 
primary hypoadrenalism reported in other recent African studies 
involving similar patient cohorts.9,17 It is difficult to interpret the lower 
than expected mean levels of serum ACTH in both study groups on 
admission to hospital.  Since pre-existing basal levels of ACTH were 
unknown, we cannot say whether the recorded values represented 
some increase from healthy baseline status.  During subsequent 
days of sampling, transient elevations were clearly seen but levels 
had returned to normal by day 5. This observation is similar to a 
previous report of normal ACTH levels despite raised cortisol in acute 
pneumonia.10
Finally, the occurrence of SIADH was the commonest metabolic 
abnormality encountered in our patients, having been diagnosed in 
about one-third of cases on admission to hospital. This figure is higher 
than the 10% prevalence rate reported in the recent study by Kaplan et 
al.9 and may be ascribed to most of our patients being HIV seropositive 
and having had more advanced disease, despite similar diagnostic 
criteria being employed. The mechanisms involved relate to increased 
total body water with decreased total body sodium as a consequence 
of enhanced or an abnormal pattern of ADH release.18
In conclusion, 40% of the entire cohort of 20 patients showed relatively 
impaired cortisol responses to ACTH stimulation on admission, but the 
significance of this is uncertain in view of extremely raised basal levels 
in most cases. During the first few days of therapy, rifampicin did not 
impair adrenal responses to conventional ACTH stimulation tests in 
this relatively small group of patients with active pulmonary TB, most 
of whom were HIV seropositive. Our finding, however, may not apply 
to occasional patients who have compromised adrenal function at the 
time of their initial admission to hospital or who are more acutely ill.
We thank Bayer (Pty) Ltd for supplying ciprofloxacin for the study, Ms A van 
der Bergh, head pharmacist at Johannesburg Hospital, for arranging the use 
of anti-tuberculosis drugs, Professor Hendrik Koornhoff of the Department of 
Microbiology, University of the Witwatersrand, for expert advice regarding the 
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